Can-Fite BioPharma (CANF) delays 2026 shareholder meeting after no quorum
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Can-Fite BioPharma Ltd. held its 2026 Annual General Meeting of Shareholders on May 28, 2026, but the meeting was adjourned because there were not enough shareholders present to meet the required quorum. The meeting is scheduled to reconvene on June 4, 2026 at 3:00 p.m. Israel time at the company’s offices in Ramat Gan, Israel.
Positive
- None.
Negative
- None.
Key Terms
foreign private issuer, Annual General Meeting of Shareholders, quorum, Form 20-F
4 terms
foreign private issuer regulatory
"FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
quorum regulatory
"the Meeting was adjourned for one week ... due to lack of quorum."
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
Form 20-F regulatory
"whether the registrant files or will file annual reports under cover Form 20-F"
Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.
FAQ
What did Can-Fite BioPharma Ltd. (CANF) report in this Form 6-K?
Can-Fite BioPharma reported that its 2026 Annual General Meeting of Shareholders convened on May 28, 2026 but was adjourned due to lack of quorum, and will reconvene on June 4, 2026.
Why was Can-Fite BioPharma’s 2026 Annual General Meeting adjourned?
The 2026 Annual General Meeting of Shareholders was adjourned because a quorum was not present. Without sufficient shareholder participation to meet quorum requirements, the company could not conduct formal business at the meeting.
Where is Can-Fite BioPharma’s reconvened 2026 Annual General Meeting being held?
The reconvened 2026 Annual General Meeting will be held at Can-Fite BioPharma’s offices at 26 Ben Gurion Street, Ramat Gan, Israel, on June 4, 2026 at 3:00 p.m. Israel time.
What type of SEC filer is Can-Fite BioPharma Ltd.?
Can-Fite BioPharma Ltd. is a foreign private issuer that files its annual reports with the SEC on Form 20-F, as indicated in the Form 6-K cover information.
Who signed the May 2026 Form 6-K for Can-Fite BioPharma (CANF)?
The Form 6-K dated May 28, 2026 was signed on behalf of Can-Fite BioPharma Ltd. by Motti Farbstein, who serves as Chief Executive Officer and Chief Financial Officer.